Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study. | Adv Ther;38(8): 4599-4601, 2021 Aug. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.

Nakamura, Ichiro; Maegawa, Hiroshi; Tobe, Kazuyuki; Uno, Satoshi.

Affiliation

Nakamura I; Astellas Pharma Inc., Tokyo, Japan. ichiro.nakamura@astellas.com.
Maegawa H; Department of Medicine, Shiga University of Medical Science, Shiga, Japan.
Tobe K; First Department of Internal Medicine, University of Toyama, Toyama, Japan.
Uno S; Astellas Pharma Inc., Tokyo, Japan.

Adv Ther ; 38(8): 4599-4601, 2021 Aug.

Article in En | MEDLINE | ID: mdl-34279807

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Screening_studies Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2021 Document type: Article Affiliation country: Japan

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Screening_studies Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2021 Document type: Article Affiliation country: Japan